Matthew Sykes
Stock Analyst at Goldman Sachs
(3.69)
# 705
Out of 4,840 analysts
205
Total ratings
48.59%
Success rate
6.32%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $4.15 | +20.48% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $2.57 | +16.73% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $8.59 | -24.33% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $37.15 | +21.13% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.15 | +92.77% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $29.41 | +63.21% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $12.43 | +36.77% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $131.38 | +21.78% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.50 | +33.33% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $92.23 | +35.53% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.15 | +6.46% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $189.18 | +26.86% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $17.61 | +47.64% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $138.65 | +22.61% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $39.17 | +42.97% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $69.99 | +14.30% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $0.91 | +64.80% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $157.16 | +20.90% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.77 | +126.39% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.24 | +90.16% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $27.97 | +32.28% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $56.56 | +14.92% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $140.54 | +77.89% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.09 | +371.98% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,162.84 | +11.80% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $6.79 | +76.73% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $403.55 | +58.59% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $111.26 | +30.33% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $43.85 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $4.15
Upside: +20.48%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $2.57
Upside: +16.73%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $8.59
Upside: -24.33%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $37.15
Upside: +21.13%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.15
Upside: +92.77%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $29.41
Upside: +63.21%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $12.43
Upside: +36.77%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $131.38
Upside: +21.78%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.50
Upside: +33.33%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $92.23
Upside: +35.53%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.15
Upside: +6.46%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $189.18
Upside: +26.86%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $17.61
Upside: +47.64%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $138.65
Upside: +22.61%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $39.17
Upside: +42.97%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $69.99
Upside: +14.30%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $0.91
Upside: +64.80%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $157.16
Upside: +20.90%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.77
Upside: +126.39%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.24
Upside: +90.16%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $27.97
Upside: +32.28%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $56.56
Upside: +14.92%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $140.54
Upside: +77.89%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.09
Upside: +371.98%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,162.84
Upside: +11.80%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $6.79
Upside: +76.73%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $403.55
Upside: +58.59%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $111.26
Upside: +30.33%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $43.85
Upside: -